A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
AIMS: Effective weight management pharmacotherapies are a new alternative to bariatric surgery or health behaviour intervention (HBI) alone. Comparative cost-effectiveness evaluations can guide decision-making. We aimed to evaluate the cost-effective…
AIM: To understand treatment patterns and effectiveness of tirzepatide among people without type 2 diabetes (T2D) in the US. METHODS: This retrospective, observational, descriptive study used the Healthcare Integrated Research Database (index date: f…
OBJECTIVE: To summarize the current knowledge on the therapeutic potential of GLP-1 receptor agonists in managing metabolic associated steatotic liver disease (MASLD). DATA SOURCES: A literature review was conducted using the search terms,,,,, andon…
OBJECTIVE: Increases in adiposity and adverse changes in adipose distribution commonly occur in women during midlife and with the onset of menopause. This post hoc analysis assessed body weight changes with tirzepatide by reproductive stage. METHODS:…
Obesity and type 2 diabetes are major risk factors for cardiovascular diseases and multiple malignancies, and epidemiology reveals an increasing burden of obesity-related cancers, in particular liver, pancreatic and endometrial. Obesity is also clear…
AIMS: This participant-level exploratory analysis assessed the continuous time spent in glycaemic control and/or with sustained weight reductions with tirzepatide treatment in participants with type 2 diabetes (T2D) from the SURPASS programme. MATERI…
BACKGROUND AND AIMS: There is limited data about tirzepatide's (TZP) efficacy for weight loss in patients with inflammatory bowel disease (IBD). METHODS: A retrospective cohort study was conducted using the US Collaborative Network in patients with I…
PURPOSE OF REVIEW: Researchers and clinicians have increasingly recognized the importance of investigating and considering sex differences in obesity treatment. In this narrative review, we first summarized sex differences in select obesity-related c…
BACKGROUND & AIMS: In the SYNERGY-NASH trial for metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis, tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, ef…
AIMS: This real-world study compared clinical outcomes between tirzepatide treatment and bariatric metabolic surgery (BMS) in adults with obesity. METHODS: This retrospective cohort study used the TriNetX network to identify adults with a body mass i…
INTRODUCTION: In SURMOUNT-2, a phase 3, randomized clinical trial, tirzepatide treatment resulted in clinically meaningful reduction in bodyweight among people with obesity or overweight and T2D. The current analysis evaluated the effects of tirzepat…
Tirzepatide, a dual glucagon-like peptide-1 receptor and gastric inhibitory peptide receptor agonist, is an effective treatment for type 2 diabetes mellitus and obesity, resulting in significant improvements in glycated hemoglobin levels and weight r…
Obesity is a growing global epidemic and a major risk factor for cardiovascular disease. However, previous weight loss interventions have largely failed to demonstrate consistent cardiovascular benefits. While lifestyle modifications remain the corne…
Alzheimer's disease (AD), the leading cause of dementia, involves microglial activation, pro-inflammatory cytokine release, and impaired insulin signaling via insulin receptor substrate 1 (IRS-1) inhibition. Brain insulin resistance (BIR) is a key fa…
AIMS: This study compares the therapeutic efficacy, gastrointestinal (GI) adverse event (AE) rates and the relationship between the therapeutic efficacy and GI AEs in randomized, placebo-controlled clinical trials (RCTs) of GLP-1 RAs and the dual GLP…
This case report highlights the multidisciplinary team (MDT) approach in managing a 49-year-old male with super-super obesity (initial Body Mass Index (BMI): 106.25 kg/m). Interventions included very-low-calorie-diet, tirzepatide treatment, and event…
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Endocrinology: [Formula: see text].
There have been many recent advancements in cardiology research, with numerous studies published across the multiple subspecialties. Having screened more than 1200 articles published in 2024, we summarize 10 studies in this article that highlight key…
Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss. There is a lack of data evaluating the types of reactions associated wit…